Method of treating protozoal gastrointestinal disorders in immunocompromised patients

A method of treating cryptosporidiosis or isosporiasis in an immunocompromised animal which comprises:

• administering to said immunocompromised animal a product comprised of a vitamin and mineral blend (Vitamins B1, B2, B6, B12, Folate, D3, C, E, and minerals Magnesium and Zinc), probiotics, including but not limited to Lactobacillus and Bifidobacterium species, mixed with a hyperimmune milk product containing a biologically active component which reduces a number of oocysts in a stool, reduces a number of Cryptosporidia or Isospora parasites in an intestine or alleviates symptoms of cryptosporidiosis or isosporiasis in a subject infected with Cryptosporidia or Isospora from a hyperimmunized milk-producing mammal selected from the group consisting of cows, sheep, and goats, in amounts sufficient to treat said cryptosporidiosis or isosporiasis, wherein said hyperimmune milk product is selected from the group consisting of hyperimmune whole milk, hyperimmune whole milk fractions, and derivatives of hyperimmune whole milk, selected from the group consisting of hyperimmune skim milk, whey, protein concentrates, and isolates, which contain said biologically active component and is prepared by a process comprising:
• (i) hyperimmunizing said milk-producing mammal with a mixture of heat-killed, non-protozoan bacterial antigens consisting of Staphylococcus simulans;
• Salmonella enteritidis;
• Streptococcus pneumoniae;
• Streptococcus sanguis;
• Streptococcus salivarius;
• Staphylococcus epidermidis;
• Streptococcus pyogenes, A. Type 1;
• Streptococcus pyogenes, A. Type 3;
• Streptococcus pyogenes, A. Type 5;
• Streptococcus pyogenes, A. Type 8;
• Streptococcus pyogenes, A. Type 12;
• Streptococcus pyogenes, A. Type 14;
• Streptococcus pyogenes, A. Type 18;
• Streptococcus pyogenes, A. Type 22;
• Escherichia coli;
• Escherichia coli ATCC 884;
• Escherichia coli ATCC 26;
• Salmonella enteritidis;
• Pseudomonas aeruginosa, Klebsiella pneumoniae, Salmonella typhimurium, Haemophilus influenza;
• Streptococcus mitis;
• Proteus vulgaris;
• Shigella dysenteriae;
• Streptococcus pneumonia;
• Propionibacter acnes;
• Streptococcus sanguis;
• Streptococcus salivarius;
• Streptococcus mutans;
• and Streptococcus agalactiae;
• (ii) collecting milk from said milk-producing mammal after said milk-producing mammal reaches a hyperimmune state;
• (iii) filtering said milk through a molecular sieve which excludes proteins of molecular weight greater than 100,000 daltons;
• (iv) blending said filtered milk retentate with the said vitamin and mineral blend and probiotics;
• and
• (v) testing the blend of step (iv) for its ability to reduce the number of oocysts in the stool, reduce the number of Cryptosporidia or Isospora parasites in the intestine or alleviate symptoms of cryptosporidiosis or isosporiasis in a subject infected with Cryptosporidia or Isospora by administering to said subject the blend of step (iv) and measuring the reduction of said oocysts, parasites, or symptoms.